CN108866101A - 人源化il-6和il-6受体 - Google Patents
人源化il-6和il-6受体 Download PDFInfo
- Publication number
- CN108866101A CN108866101A CN201810620759.8A CN201810620759A CN108866101A CN 108866101 A CN108866101 A CN 108866101A CN 201810620759 A CN201810620759 A CN 201810620759A CN 108866101 A CN108866101 A CN 108866101A
- Authority
- CN
- China
- Prior art keywords
- mouse
- gene
- people
- source
- humanization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 250
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 196
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title description 98
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title description 91
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 94
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 42
- 230000033228 biological regulation Effects 0.000 claims abstract description 15
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims abstract 21
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims abstract 21
- 210000004027 cell Anatomy 0.000 claims description 89
- 238000012239 gene modification Methods 0.000 claims description 48
- 101000599053 Mus musculus Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 36
- 241001529936 Murinae Species 0.000 claims description 30
- 210000000952 spleen Anatomy 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 26
- 230000001276 controlling effect Effects 0.000 claims description 25
- 101150087698 alpha gene Proteins 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 21
- 206010048998 Acute phase reaction Diseases 0.000 claims description 20
- 230000004658 acute-phase response Effects 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 101100286719 Mus musculus Il6 gene Proteins 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 108700024394 Exon Proteins 0.000 claims description 13
- 210000000805 cytoplasm Anatomy 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- 238000010010 raising Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000002981 blocking agent Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 6
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 206010041660 Splenomegaly Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000022532 enlargement of lymph nodes Diseases 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 210000001501 megacaryocyte Anatomy 0.000 claims description 6
- 101100452395 Mus musculus Il6ra gene Proteins 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 210000002231 macronucleus Anatomy 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 296
- 229940100601 interleukin-6 Drugs 0.000 description 176
- 241000699670 Mus sp. Species 0.000 description 69
- 210000003719 b-lymphocyte Anatomy 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 35
- 238000011830 transgenic mouse model Methods 0.000 description 35
- 241000699660 Mus musculus Species 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 238000000684 flow cytometry Methods 0.000 description 21
- 206010020718 hyperplasia Diseases 0.000 description 20
- 238000001514 detection method Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 238000004043 dyeing Methods 0.000 description 15
- 102000014150 Interferons Human genes 0.000 description 14
- 108010050904 Interferons Proteins 0.000 description 14
- 238000011529 RT qPCR Methods 0.000 description 14
- 229940079322 interferon Drugs 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 101150047862 hil-6 gene Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 102000005869 Activating Transcription Factors Human genes 0.000 description 9
- 108010005254 Activating Transcription Factors Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 8
- 102100022338 Integrin alpha-M Human genes 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010025815 Kanamycin Kinase Proteins 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 7
- 210000004885 white matter Anatomy 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 6
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 6
- 102100038081 Signal transducer CD24 Human genes 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000013394 immunophenotyping Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000003593 megakaryocyte Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical group CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 208000007452 Plasmacytoma Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 4
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 4
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 239000001293 FEMA 3089 Substances 0.000 description 4
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102100039564 Leukosialin Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000011712 cell development Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 102000006734 Beta-Globulins Human genes 0.000 description 3
- 108010087504 Beta-Globulins Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 101710190759 Serum amyloid A protein Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 241001105470 Valenzuela Species 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 108010053584 alpha-Globins Proteins 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108020004509 Intracisternal A-Particle Genes Proteins 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010073599 Myeloma cast nephropathy Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000000280 pituicyte Anatomy 0.000 description 1
- 206010035485 plasmacytosis Diseases 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000007342 reactive astrogliosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552900P | 2011-10-28 | 2011-10-28 | |
| US61/552,900 | 2011-10-28 | ||
| US201161556579P | 2011-11-07 | 2011-11-07 | |
| US61/556,579 | 2011-11-07 | ||
| CN201280065013.6A CN104039821A (zh) | 2011-10-28 | 2012-10-29 | 人源化il-6和il-6受体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280065013.6A Division CN104039821A (zh) | 2011-10-28 | 2012-10-29 | 人源化il-6和il-6受体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108866101A true CN108866101A (zh) | 2018-11-23 |
Family
ID=47295138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810620759.8A Pending CN108866101A (zh) | 2011-10-28 | 2012-10-29 | 人源化il-6和il-6受体 |
| CN201280065013.6A Pending CN104039821A (zh) | 2011-10-28 | 2012-10-29 | 人源化il-6和il-6受体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280065013.6A Pending CN104039821A (zh) | 2011-10-28 | 2012-10-29 | 人源化il-6和il-6受体 |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8878001B2 (https=) |
| EP (2) | EP2663575B1 (https=) |
| JP (2) | JP6120451B2 (https=) |
| KR (2) | KR102234632B1 (https=) |
| CN (2) | CN108866101A (https=) |
| AU (1) | AU2015207889B2 (https=) |
| BR (1) | BR112014008529A2 (https=) |
| CA (1) | CA2853731C (https=) |
| CY (2) | CY1116614T1 (https=) |
| DK (2) | DK2818478T3 (https=) |
| ES (2) | ES2624605T3 (https=) |
| HR (2) | HRP20141192T1 (https=) |
| HU (1) | HUE033400T2 (https=) |
| IL (4) | IL231896B (https=) |
| IN (1) | IN2014CN03920A (https=) |
| LT (1) | LT2818478T (https=) |
| MX (1) | MX358390B (https=) |
| MY (2) | MY172726A (https=) |
| PL (2) | PL2663575T3 (https=) |
| PT (2) | PT2663575E (https=) |
| RS (2) | RS55949B1 (https=) |
| RU (2) | RU2751240C2 (https=) |
| SG (3) | SG10202100485XA (https=) |
| SI (2) | SI2818478T1 (https=) |
| SM (2) | SMT201700222T1 (https=) |
| WO (1) | WO2013063556A1 (https=) |
| ZA (1) | ZA201402635B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304246A (zh) * | 2019-12-17 | 2020-06-19 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
| CN113853433A (zh) * | 2019-05-27 | 2021-12-28 | 转基因股份有限公司 | 外显子人源化小鼠 |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2485583T (pt) | 2009-10-06 | 2016-09-22 | Univ Yale | Ratinhos geneticamente modificados e enxerto |
| MX350385B (es) | 2011-02-15 | 2017-09-04 | Regeneron Pharma | Ratones de m-csf humanizada. |
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| US20130261016A1 (en) * | 2012-03-28 | 2013-10-03 | Meso Scale Technologies, Llc | Diagnostic methods for inflammatory disorders |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| IN2015DN02032A (https=) | 2012-09-07 | 2015-08-14 | Univ Yale | |
| WO2014042251A1 (ja) * | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| PL2958937T3 (pl) | 2013-02-22 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej |
| GB2513884B (en) | 2013-05-08 | 2015-06-17 | Univ Bristol | Method and apparatus for producing an acoustic field |
| CN105592695B (zh) * | 2013-09-23 | 2018-04-10 | 瑞泽恩制药公司 | 具有人源化信号调节蛋白基因的非人动物 |
| ES2715949T3 (es) | 2013-10-15 | 2019-06-07 | Regeneron Pharma | Animales con IL-15 humanizada |
| SG10201811701YA (en) * | 2013-11-19 | 2019-01-30 | Regeneron Pharma | Non-human animals having a humanized a proliferation-inducing ligand gene |
| CA2929846C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| US9612658B2 (en) | 2014-01-07 | 2017-04-04 | Ultrahaptics Ip Ltd | Method and apparatus for providing tactile sensations |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| HUE051088T2 (hu) | 2014-04-08 | 2021-03-01 | Regeneron Pharma | Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények |
| SG10202003996YA (en) | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
| NO2785538T3 (https=) * | 2014-05-07 | 2018-08-04 | ||
| SG10202002187WA (en) | 2014-05-19 | 2020-04-29 | Regeneron Pharma | Genetically modified non-human animals expressing human epo |
| US9497945B2 (en) * | 2014-05-30 | 2016-11-22 | Regeneron Pharmaceuticals, Inc. | Humanized dipeptidyl peptidase IV (DPP4) animals |
| ES2783424T3 (es) * | 2014-06-19 | 2020-09-17 | Regeneron Pharma | Animales no humanos que tienen un gen de muerte celular programada 1 humanizado |
| GB2530036A (en) | 2014-09-09 | 2016-03-16 | Ultrahaptics Ltd | Method and apparatus for modulating haptic feedback |
| RU2020122439A (ru) | 2014-11-24 | 2020-09-24 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| SI3086637T1 (sl) * | 2014-12-05 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Nehumane živali s humaniziranim označevalcem diferenciacije gena CD47 |
| HUE052606T2 (hu) | 2014-12-09 | 2021-05-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| SG11201706527QA (en) | 2015-02-20 | 2017-09-28 | Ultrahaptics Ip Ltd | Algorithm improvements in a haptic system |
| WO2016132144A1 (en) | 2015-02-20 | 2016-08-25 | Ultrahaptics Ip Limited | Perceptions in a haptic system |
| CN113349159B (zh) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | 非人动物中的人源化t细胞介导的免疫应答 |
| KR102658190B1 (ko) | 2015-04-13 | 2024-04-17 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법 |
| US10818162B2 (en) | 2015-07-16 | 2020-10-27 | Ultrahaptics Ip Ltd | Calibration techniques in haptic systems |
| SG11201803409UA (en) | 2015-11-20 | 2018-05-30 | Regeneron Pharma | Non-human animals having a humanized lymphocyte-activation gene 3 |
| AU2016365834B2 (en) | 2015-12-08 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| US11189140B2 (en) | 2016-01-05 | 2021-11-30 | Ultrahaptics Ip Ltd | Calibration and detection techniques in haptic systems |
| MX2018009513A (es) | 2016-02-04 | 2019-01-31 | Regeneron Pharma | Animales no humanos que tienen un gen angptl8 modificado genéticamente. |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| HUE061619T2 (hu) | 2016-06-03 | 2023-07-28 | Regeneron Pharma | Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók |
| US10531212B2 (en) | 2016-06-17 | 2020-01-07 | Ultrahaptics Ip Ltd. | Acoustic transducers in haptic systems |
| US10268275B2 (en) | 2016-08-03 | 2019-04-23 | Ultrahaptics Ip Ltd | Three-dimensional perceptions in haptic systems |
| US10755538B2 (en) | 2016-08-09 | 2020-08-25 | Ultrahaptics ilP LTD | Metamaterials and acoustic lenses in haptic systems |
| CN107815467B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| US10943578B2 (en) | 2016-12-13 | 2021-03-09 | Ultrahaptics Ip Ltd | Driving techniques for phased-array systems |
| US10497358B2 (en) | 2016-12-23 | 2019-12-03 | Ultrahaptics Ip Ltd | Transducer driver |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| MX394999B (es) | 2017-09-29 | 2025-03-24 | Regeneron Pharma | Animales no humanos que comprenden un locus ttr humanizado y metodos de uso |
| US11531395B2 (en) | 2017-11-26 | 2022-12-20 | Ultrahaptics Ip Ltd | Haptic effects from focused acoustic fields |
| IL310006A (en) | 2017-11-30 | 2024-03-01 | Regeneron Pharma | Non-human animals containing a humanized TRKB locus |
| EP3729418B1 (en) | 2017-12-22 | 2024-11-20 | Ultrahaptics Ip Ltd | Minimizing unwanted responses in haptic systems |
| EP3729417B1 (en) | 2017-12-22 | 2025-09-10 | Ultrahaptics Ip Ltd | Tracking in haptic systems |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| SG11202010752VA (en) | 2018-05-02 | 2020-11-27 | Ultrahaptics Ip Ltd | Blocking plate structure for improved acoustic transmission efficiency |
| IL278267B2 (en) * | 2018-07-16 | 2025-02-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| US11098951B2 (en) | 2018-09-09 | 2021-08-24 | Ultrahaptics Ip Ltd | Ultrasonic-assisted liquid manipulation |
| US11378997B2 (en) | 2018-10-12 | 2022-07-05 | Ultrahaptics Ip Ltd | Variable phase and frequency pulse-width modulation technique |
| WO2020125639A1 (en) * | 2018-12-17 | 2020-06-25 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| EP3906462B1 (en) | 2019-01-04 | 2025-06-18 | Ultrahaptics IP Ltd | Mid-air haptic textures |
| US12373033B2 (en) | 2019-01-04 | 2025-07-29 | Ultrahaptics Ip Ltd | Mid-air haptic textures |
| WO2020147829A1 (zh) * | 2019-01-17 | 2020-07-23 | 北京百奥赛图基因生物技术有限公司 | 人源化转基因动物 |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| US11842517B2 (en) | 2019-04-12 | 2023-12-12 | Ultrahaptics Ip Ltd | Using iterative 3D-model fitting for domain adaptation of a hand-pose-estimation neural network |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| CA3154040A1 (en) | 2019-10-13 | 2021-04-22 | Benjamin John Oliver LONG | Dynamic capping with virtual microphones |
| US11374586B2 (en) | 2019-10-13 | 2022-06-28 | Ultraleap Limited | Reducing harmonic distortion by dithering |
| US11169610B2 (en) | 2019-11-08 | 2021-11-09 | Ultraleap Limited | Tracking techniques in haptic systems |
| US11715453B2 (en) | 2019-12-25 | 2023-08-01 | Ultraleap Limited | Acoustic transducer structures |
| EP4096396A1 (en) * | 2020-01-28 | 2022-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| WO2021216505A1 (en) | 2020-04-21 | 2021-10-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cxcl13 gene |
| US11816267B2 (en) | 2020-06-23 | 2023-11-14 | Ultraleap Limited | Features of airborne ultrasonic fields |
| WO2022058738A1 (en) | 2020-09-17 | 2022-03-24 | Ultraleap Limited | Ultrahapticons |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| US12517585B2 (en) | 2021-07-15 | 2026-01-06 | Ultraleap Limited | Control point manipulation techniques in haptic systems |
| WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100445A (en) * | 1994-10-14 | 2000-08-08 | Basf Aktiengesellschaft | Transgenic knockout mouse having functionally disrupted interleukin-1β converting enzyme gene |
| CN101506235A (zh) * | 2006-09-01 | 2009-08-12 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
| WO2011084664A1 (en) * | 2009-12-21 | 2011-07-14 | Regeneron Pharmaceuticals, Inc. | HUMANIZED FCγ R MICE |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306963C (zh) | 1994-10-21 | 2007-03-28 | 岸本忠三 | 用于治疗il－6产生所致疾病的药物组合物 |
| US20030082721A1 (en) * | 2001-01-17 | 2003-05-01 | Tai-Jay Chang | Transgenic animals expressing androgen receptor complex-associated protein |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用 |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| US7759541B2 (en) * | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| FR2942218A1 (fr) | 2009-02-13 | 2010-08-20 | Eurocave Sa | Appareil de service au verre d'un liquide, notamment de vin |
| PT2485583T (pt) | 2009-10-06 | 2016-09-22 | Univ Yale | Ratinhos geneticamente modificados e enxerto |
| MX350385B (es) | 2011-02-15 | 2017-09-04 | Regeneron Pharma | Ratones de m-csf humanizada. |
| TW201945034A (zh) * | 2011-09-30 | 2019-12-01 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| SI2770821T1 (en) | 2011-10-28 | 2018-01-31 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex of mice |
| DK3590332T3 (da) | 2011-10-28 | 2022-05-23 | Regeneron Pharma | Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler |
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
-
2012
- 2012-10-29 WO PCT/US2012/062379 patent/WO2013063556A1/en not_active Ceased
- 2012-10-29 BR BR112014008529A patent/BR112014008529A2/pt not_active Application Discontinuation
- 2012-10-29 RS RS20170430A patent/RS55949B1/sr unknown
- 2012-10-29 ES ES14177863.9T patent/ES2624605T3/es active Active
- 2012-10-29 PT PT127959054T patent/PT2663575E/pt unknown
- 2012-10-29 HR HRP20141192AT patent/HRP20141192T1/hr unknown
- 2012-10-29 PL PL12795905T patent/PL2663575T3/pl unknown
- 2012-10-29 SG SG10202100485XA patent/SG10202100485XA/en unknown
- 2012-10-29 SG SG10201600965YA patent/SG10201600965YA/en unknown
- 2012-10-29 SI SI201230941A patent/SI2818478T1/sl unknown
- 2012-10-29 MX MX2014004900A patent/MX358390B/es active IP Right Grant
- 2012-10-29 IN IN3920CHN2014 patent/IN2014CN03920A/en unknown
- 2012-10-29 ES ES12795905.4T patent/ES2525368T3/es active Active
- 2012-10-29 PT PT141778639T patent/PT2818478T/pt unknown
- 2012-10-29 MY MYPI2014000768A patent/MY172726A/en unknown
- 2012-10-29 RS RS20140677A patent/RS53683B1/sr unknown
- 2012-10-29 CN CN201810620759.8A patent/CN108866101A/zh active Pending
- 2012-10-29 HU HUE14177863A patent/HUE033400T2/en unknown
- 2012-10-29 SG SG11201400945UA patent/SG11201400945UA/en unknown
- 2012-10-29 DK DK14177863.9T patent/DK2818478T3/en active
- 2012-10-29 RU RU2017129763A patent/RU2751240C2/ru active
- 2012-10-29 SM SM20170222T patent/SMT201700222T1/it unknown
- 2012-10-29 CA CA2853731A patent/CA2853731C/en active Active
- 2012-10-29 MY MYPI2017703646A patent/MY186903A/en unknown
- 2012-10-29 KR KR1020207005686A patent/KR102234632B1/ko active Active
- 2012-10-29 DK DK12795905.4T patent/DK2663575T3/en active
- 2012-10-29 RU RU2014121324A patent/RU2634417C2/ru active
- 2012-10-29 EP EP12795905.4A patent/EP2663575B1/en active Active
- 2012-10-29 CN CN201280065013.6A patent/CN104039821A/zh active Pending
- 2012-10-29 LT LTEP14177863.9T patent/LT2818478T/lt unknown
- 2012-10-29 JP JP2014539105A patent/JP6120451B2/ja active Active
- 2012-10-29 KR KR1020147014316A patent/KR102084927B1/ko active Active
- 2012-10-29 EP EP14177863.9A patent/EP2818478B1/en active Active
- 2012-10-29 PL PL14177863T patent/PL2818478T3/pl unknown
- 2012-10-29 SI SI201230111T patent/SI2663575T1/sl unknown
- 2012-10-29 US US13/662,880 patent/US8878001B2/en active Active
-
2014
- 2014-04-03 IL IL231896A patent/IL231896B/en active IP Right Grant
- 2014-04-10 ZA ZA2014/02635A patent/ZA201402635B/en unknown
- 2014-09-19 US US14/490,877 patent/US9078418B2/en active Active
- 2014-09-19 US US14/490,875 patent/US9125386B2/en active Active
- 2014-12-11 CY CY20141101035T patent/CY1116614T1/el unknown
- 2014-12-15 SM SM201400187T patent/SMT201400187B/xx unknown
-
2015
- 2015-06-10 US US14/735,710 patent/US9392777B2/en active Active
- 2015-07-30 AU AU2015207889A patent/AU2015207889B2/en active Active
-
2016
- 2016-01-18 IL IL243665A patent/IL243665B/en active IP Right Grant
- 2016-01-18 IL IL243666A patent/IL243666B/en active IP Right Grant
- 2016-06-09 US US15/177,582 patent/US9622460B2/en active Active
- 2016-11-14 US US15/350,739 patent/US10004211B2/en active Active
- 2016-11-18 JP JP2016224713A patent/JP2017035115A/ja active Pending
-
2017
- 2017-04-28 HR HRP20170656TT patent/HRP20170656T1/hr unknown
- 2017-04-28 CY CY20171100474T patent/CY1118952T1/el unknown
-
2018
- 2018-06-06 US US16/001,074 patent/US10433528B2/en active Active
-
2019
- 2019-01-28 IL IL264508A patent/IL264508B/en active IP Right Grant
- 2019-07-03 US US16/502,197 patent/US11102962B2/en active Active
-
2021
- 2021-07-26 US US17/385,039 patent/US12239111B2/en active Active
-
2025
- 2025-01-29 US US19/039,847 patent/US20250287931A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100445A (en) * | 1994-10-14 | 2000-08-08 | Basf Aktiengesellschaft | Transgenic knockout mouse having functionally disrupted interleukin-1β converting enzyme gene |
| CN101506235A (zh) * | 2006-09-01 | 2009-08-12 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
| WO2011084664A1 (en) * | 2009-12-21 | 2011-07-14 | Regeneron Pharmaceuticals, Inc. | HUMANIZED FCγ R MICE |
Non-Patent Citations (2)
| Title |
|---|
| GOYA等: "Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung", 《JOURNAL OF PATHOLOGY》 * |
| 陈惠鹏: "《医学生物工程进展》", 31 July 2004 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113853433A (zh) * | 2019-05-27 | 2021-12-28 | 转基因股份有限公司 | 外显子人源化小鼠 |
| CN111304246A (zh) * | 2019-12-17 | 2020-06-19 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12239111B2 (en) | Humanized IL-6 and IL-6 receptor | |
| HK1205135B (en) | Humanized il-6 and il-6 receptor | |
| HK1190408B (en) | Humanized il-6 and il-6 receptor | |
| AU2012327206A8 (en) | Humanized IL-6 and IL-6 receptor | |
| NZ623145B2 (en) | Humanized il-6 and il-6 receptor | |
| NZ709432B2 (en) | Humanized il-6 and il-6 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |